EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium

Andres J Yarur iD, Ryan Ungaro iD, Katherine Huang, Wenfei Wang, Priya Sasankan, Mir Zulqarnain, Amanda M Johnson, Geoffrey Bader, Carl Kay, Nicholas Costable, David Dulaney, Marc Fenster und 7 weitere

Inflammatory Bowel Diseases · 06.01.2025 · 31 (1) · 131-139

DOI: 10.1093/ibd/izae058 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 26.03.2024. Verfasst von Andres J Yarur und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA. Hauptthemen laut MEDLINE: Ustekinumab, Colitis, Ulcerative, Remission Induction. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, Junior Faculty Development Award from the American College of Gastroenterology, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pivotal trials have shown that ustekinumab is effective in ulcerative colitis (UC). However, the population included in these trials do not represent the cohort of patients treated in the real world. In this study, we aimed to describe the effectiveness and safety of ustekinumab in a clinical cohort of patients with UC.

Methods

We performed a multicenter retrospective cohort study and included patients with active UC starting ustekinumab. Variables collected included demographics, clinical data, and disease activity (measured using partial Mayo score [PMS] and endoscopic Mayo score) at follow-up. The primary outcomes were cumulative rates of steroid-free clinical and biochemical remission (SFCBR), defined as a PMS <2 while off steroids and a normal C-reactive protein and/or fecal calprotectin.

Results

A total of 245 patients met inclusion criteria. The median time of follow-up was 33 (interquartile range, 17-53) weeks, and 214 (87.3%) had previous exposure to a biologic and/or tofacitinib. Rates of SFCBR, clinical remission, and endoscopic remission at 6 and 12 months were 12.0% (n = 16 of 139), 29.0% (n = 71 of 175), and 18.0% (n = 7 of 39), and 23.8% (n = 15 of 63), 54.3% (n = 57 of 105), and 31.0% (n = 9 of 29), respectively. Non-Hispanic White race, higher baseline PMS, and the use of concomitant corticosteroids were independently associated with failure to achieve SFCBR. Of the 73 that were dose escalated, 28.4% did not respond, 49.3% experienced a benefit, and 21.6% achieved remission.

Conclusions

In a population enriched with refractory UC, ustekinumab was well tolerated and induced remission in a significant number of patients. Larger studies with a longer follow-up are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabColitis, UlcerativeRemission InductionHumansFemaleMaleRetrospective StudiesAdultMiddle AgedUnited StatesTreatment OutcomeFollow-Up StudiesSeverity of Illness Index

Stichwörter der Autor:innen

colectomydose escalationefficacyulcerative colitisustekinumab

Substanzen

Ustekinumab

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Division of Gastroenterology and Hepatology, Inflammatory Bowel Disease Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.
  • Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mt. Sinai, New York, NY, USA.
  • Inflammatory Bowel Disease Center, Division of Gastroenterology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA.
  • Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA.

ORCID-Profile: Andres J Yarur, Ryan Ungaro, Parakkal Deepak

Förderung

  • NCATS NIH HHS
  • Junior Faculty Development Award from the American College of Gastroenterology
  • NIH HHS
  • NIDDK NIH HHS
  • Clinical and Translational Science Award
  • National Center for Advancing Translational Sciences
  • National Institutes of Health

Zitieren

APA

Yarur, A. J., Ungaro, R., Huang, K., Wang, W., Sasankan, P., Zulqarnain, M., Johnson, A. M., Bader, G., Kay, C., Costable, N., Dulaney, D., Fenster, M., Beniwal-Patel, P., Syal, G., Patel, A., Loftus, E., Pekow, J., Cohen, B., & Deepak, P. (2025). Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium. Inflammatory Bowel Diseases, 31(1), 131-139. https://doi.org/10.1093/ibd/izae058

Vancouver

Yarur AJ, Ungaro R, Huang K, Wang W, Sasankan P, Zulqarnain M, et al. Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium. Inflammatory Bowel Diseases. 2025;31(1):131-139. doi:10.1093/ibd/izae058

BibTeX
@article{Yarur2025,
  author = {Yarur, Andres J and Ungaro, Ryan and Huang, Katherine and Wang, Wenfei and Sasankan, Priya and Zulqarnain, Mir and Johnson, Amanda M and Bader, Geoffrey and Kay, Carl and Costable, Nicholas and Dulaney, David and Fenster, Marc and Beniwal-Patel, Poonam and Syal, Gaurav and Patel, Anish and Loftus, Edward and Pekow, Joel and Cohen, Benjamin and Deepak, Parakkal},
  title = {Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {1},
  pages = {131--139},
  doi = {10.1093/ibd/izae058}
}
Kostenlos starten →